Blog Posts
Innovations Advanced by M&A: A New Medicine Treating Anemia for Patients with Myelofibrosis
GlaxoSmithKline (GSK)’s 2022 acquisition of Sierra Oncology combined Sierra’s specialization in developing targeting therapies for rare blood cancers with GSK’s global scale, regulatory experience and commercialization capabilities — leading to approval of the only first-line medicine to treat myelofibrosis patients who have anemia.
M&A Powers Innovation to Fill Unmet Medical Needs
To address the unmet medical needs of those with rare diseases requires groundbreaking science in diseases that are not well understood, and this high degree of complexity often means that mergers and acquisitions (M&A) are critically important for companies to be successful in bringing new treatments to patients.
Legal Experts Signal Continued Uncertainty for Life Sciences M&A
Recent commentary from senior Federal Trade Commission (FTC) and Department of Justice (DOJ) officials signaled a continued commitment to an activist antitrust enforcement – compounding the uncertainty for thousands of small and early-state life science companies that depend on mergers and acquisitions (M&A) to bring new treatments to patients.
New Study Finds that Biopharmaceutical M&A Drives Innovation Through New and Novel Drug Launches
In a recent study published in Concurrences Law & Economics, Cornerstone Research experts found a significant association between biopharmaceutical mergers and acquisitions (M&A) and the likelihood of new and novel therapies coming to market.
Partner Blog: “Indiana’s Life Sciences: How Collaboration Fuels Innovation and Patient Impact”
Pro-competitive mergers and acquisitions (M&A) have been critical to Indiana’s success by facilitating dynamic partnerships among our state’s universities, academic researchers and life sciences companies of all sizes.
Pro-Competitive Partnerships: The Engine of U.S. Life Sciences Innovations
Following a recent Trump Administration executive order, the Federal Trade Commission (FTC) and Department of Justice (DOJ) both released statements signaling a shift to a more balanced approach to mergers and acquisitions (M&A) enforcement.
General Catalyst: Pro-Competitive Partnerships Drive “Steady Drumbeat of Innovation” in the Life Sciences
Investment in early-stage life sciences companies is critical to sustain America’s global leadership in discovering and developing new medical breakthroughs for patients, according to a recent General Catalyst blog, “The Future of Life Sciences Investment.”
Innovations Advanced by M&A: A New Therapy for Ulcerative Colitis
The acquisition of Arena Pharmaceuticals by Pfizer in 2022 enabled the development and commercialization of Velsipity (etrasimod), an innovative therapy for moderate to severe ulcerative colitis (UC).
NYU Law Review: Antitrust Overreach Risks Chilling Investment in Early-Stage Innovations
In their recent New York University Law Review article, “No Exit,” Matthew Wansley and Samuel Weinstein discuss how the Federal Trade Commission (FTC) and Department of Justice (DOJ)’s approach toward M&A is obstructing a critical exit point for innovative early-stage companies.
Deseret News Op-Ed: “To support biopharmaceutical breakthroughs in Utah, it’s time to revisit federal merger policies”
In a recent op-ed for Deseret News, Kelvyn Cullimore, CEO of PULSE Partner BioUtah, emphasizes the importance of federal policies that support pro-competitive life sciences mergers and acquisitions (M&A), in order to sustain innovation and growth in the life sciences — in Utah and across the country.